322 related articles for article (PubMed ID: 17078916)
1. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004.
Likeufack AC; Brun R; Fomena A; Truc P
Acta Trop; 2006 Nov; 100(1-2):11-6. PubMed ID: 17078916
[TBL] [Abstract][Full Text] [Related]
2. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
Maina N; Maina KJ; Mäser P; Brun R
Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
[TBL] [Abstract][Full Text] [Related]
3. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
5. The phenomenon of treatment failures in Human African Trypanosomiasis.
Brun R; Schumacher R; Schmid C; Kunz C; Burri C
Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
[TBL] [Abstract][Full Text] [Related]
6. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.
Graf FE; Ludin P; Wenzler T; Kaiser M; Brun R; Pyana PP; Büscher P; de Koning HP; Horn D; Mäser P
PLoS Negl Trop Dis; 2013; 7(10):e2475. PubMed ID: 24130910
[TBL] [Abstract][Full Text] [Related]
8. Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania.
Kibona SN; Matemba L; Kaboya JS; Lubega GW
Trop Med Int Health; 2006 Feb; 11(2):144-55. PubMed ID: 16451338
[TBL] [Abstract][Full Text] [Related]
9. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
Iten M; Matovu E; Brun R; Kaminsky R
Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023
[TBL] [Abstract][Full Text] [Related]
10. [Melarsoprol].
Simon F
Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741
[No Abstract] [Full Text] [Related]
11. Veterinary link to drug resistance in human African trypanosomiasis?
Barrett MP
Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
[No Abstract] [Full Text] [Related]
12. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility.
Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C
Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658
[TBL] [Abstract][Full Text] [Related]
13. Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance.
Bernhard SC; Nerima B; Mäser P; Brun R
Int J Parasitol; 2007 Nov; 37(13):1443-8. PubMed ID: 17602691
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa.
Truc P; Lejon V; Magnus E; Jamonneau V; Nangouma A; Verloo D; Penchenier L; Büscher P
Bull World Health Organ; 2002; 80(11):882-6. PubMed ID: 12481210
[TBL] [Abstract][Full Text] [Related]
15. [The return of sleeping sickness in an epidemic form: international action for drugs].
Kager PA
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2527-30. PubMed ID: 12532663
[TBL] [Abstract][Full Text] [Related]
16. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes.
de Koning HP
Trends Parasitol; 2008 Aug; 24(8):345-9. PubMed ID: 18599351
[TBL] [Abstract][Full Text] [Related]
17. Cynaropicrin: the first plant natural product with in vivo activity against Trypanosoma brucei.
Zimmermann S; Kaiser M; Brun R; Hamburger M; Adams M
Planta Med; 2012 Apr; 78(6):553-6. PubMed ID: 22331812
[TBL] [Abstract][Full Text] [Related]
18. [Three patients with African sleeping sickness following a visit to Tanzania].
Mendonça Melo M; Rasica M; van Thiel PP; Richter C; Kager PA; Wismans PJ
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2552-6. PubMed ID: 12532670
[TBL] [Abstract][Full Text] [Related]
19. Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates.
Graf FE; Baker N; Munday JC; de Koning HP; Horn D; Mäser P
Int J Parasitol Drugs Drug Resist; 2015 Aug; 5(2):65-8. PubMed ID: 26042196
[TBL] [Abstract][Full Text] [Related]
20. In vitro drug sensitivity of Trypanosoma gambiense isolates.
Brun R; Baeriswyl S; Kunz C
Acta Trop; 1989 Oct; 46(5-6):369-76. PubMed ID: 2575872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
